These results provided evidence for the first time to suggest that the ROS-activated GCN2-eIF2α-ATF4-xCT pathway is retrograde signaling that contributes to mitochondrial dysfunction-enhanced cisplatin resistance in human gastric cancer cells (Figure 9D). This evidence concerns the gene EIF2A and gastric cancer.